FDA bar certain cattle material from medical products19 January 2007
The US Food and Drug Administration is proposing to limit the materials used in some medical products in order to keep them free of the agent thought to cause bovine spongiform encephalopathy (BSE). This is the latest in a series of safeguards that would bar material that has been found to harbour the highest concentrations of this fatal agent in infected cattle. These materials would be prohibited from use as ingredients in medical products or elements of product manufacturing. The proposed rule would cover drugs (prescription, over-the-counter and homeopathic), biologics (such as vaccines) and medical devices intended for use in humans as well as drugs intended for use in ruminant animals like cattle and sheep. 'These measures build on a series of barriers that FDA and the US Department of Agriculture have erected to further protect humans from exposure to the fatal agent linked to BSE', said Andrew von Eschenbach, Commissioner Food and Drugs. 'This proposed rule adds one more safeguard that will reduce the risk of transmission even further.' The cattle materials prohibited in the proposed rule are those that pose the highest risk of containing infectious material and include: the brain, skull, eyes and spinal cords from cattle 30 months and older; the tonsils and a portion of the small intestines from all cattle regardless of their age or health; any material from 'downer' cattle (those that cannot walk); any material from cattle not inspected and passed for human consumption; foetal calf serum if appropriate procedures have not been followed to prevent its contamination with materials prohibited by this proposed rule; tallow that contains more than 0.15% insoluble impurities if the tallow is derived from materials prohibited by this proposed rule and; mechanically separated beef. To ensure that companies comply with these prohibitions, FDA proposes to require that records be kept to demonstrate that any cattle material used as an ingredient in these medical products or as part of their manufacturing process meet the rule's requirements. Since 1996, strong evidence has accumulated for a causal relationship between ongoing outbreaks of mad cow disease in Europe and a disease in humans called variant Creutzfeldt-Jakob (vCJD) disease. Both disorders, which are thought to be caused by an unconventional transmissible agent, are invariably fatal brain diseases with incubation periods typically measured in years. Transmission of the BSE agent to humans, leading to vCJD, is believed to occur via ingestion of cattle products contaminated with the BSE agent; however the specific products associated with this transmission are unknown. About 200 cases of vCJD have been identified worldwide, including three cases in the US. However, there is no evidence that those three patients contracted the BSE agent in the US. FDA and USDA's efforts to help protect the public from vCJD have included several other significant steps such as the FDA's 1997 ruminant feed regulation, which forbids the use of certain mammalian-origin proteins in ruminant feed. Also, a 2005 interim final rule bans the use of certain high-risk cattle material in food, dietary supplements and cosmetics.